CALLA: Durvalumab versus placebo with chemoradiotherapy Last updated on Feb 15, 2025 Previous SCORPION: Primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer Next KEYNOTE A18: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer
